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India experienced the ﬁ  rst  con-
ﬁ  rmed outbreak of chikungunya fever 
in 1963–1964 in Kolkata (7) and in 
1965 in Chennai. The last epidemic 
in India was reported from Barsi in 
the state of Maharastra in 1973 (8). 
However, during these outbreaks, An-
daman and Nicobar Islands were not 
affected. Outbreaks of dengue fever 
and chikungunya fever are known 
to occur simultaneously, as has hap-
pened in several parts of India. How-
ever, during the current outbreak in 
Andaman Islands, dengue infection 
was not detected. (Dengue has never 
been reported in the islands.) As chi-
kungunya fever is known for its mys-
terious pattern of dramatic outbreaks 
interspersed by periods of prolonged 
absence, the introduction of this virus 
to an unexposed population has great 
public health importance. 
This outbreak could be a warning 
about preparedness for health authori-
ties not only in these islands but also 
in other areas where chikungunya fe-
ver has not occurred previously. With 
the extent of human travel to and from 
areas with active chikungunya vi-
rus transmission, many areas where 
the disease has not previously been 
reported could be at risk. As an out-
break response, the Regional Medical 
Research Centre and Directorate of 
Health Services, Andaman and Nico-
bar Administration, has undertaken a 
comprehensive community-based sur-
vey to assess the impact of chikungu-
nya fever and Aedes infestation levels. 
We are stepping up our applied ﬁ  eld 
research to prevent future outbreaks of 
chikungunya fever, as well as dengue 
fever.
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Alistipes ﬁ  negoldii 
in Blood Cultures 
from Colon Cancer 
Patients
To the Editor: Alistipes ﬁ  negol-
dii was previously isolated from ap-
pendiceal tissue samples in children 
with acute appendicitis and from 
perirectal and brain abscess material 
(1,2). 16S rDNA sequencing studies 
showed that this bacterium clustered 
with  A. putredinis (Figure) in the 
Bacteroidetes group (4). We describe 
the ﬁ  rst cases, to our knowledge, of 
bacteremia due to A. ﬁ  negoldii in 2 
patients with colon cancer who un-
derwent surgical resection.
The  ﬁ  rst patient was a 61-year-
old woman with colorectal carcinoma 
and liver metastasis, who underwent 
chemotherapy consisting of 6 cycles 
of oxaliplatin (the FOLFOX scheme, 
a chemotherapy regimen consisting of 
ﬂ  uorouracil [5 FU], folinic acid, and 
oxaliplatin). In September 2003, a left 
colectomy, resection of metastasis in 
the left side of the liver, and a ligation 
of the right portal vein were performed. 
Two months later, in a second step, a 
right hepatectomy was done. On post-
operative day 5, the patient had a fe-
ver up to 39.8°C and leukocyte count 
of 8.49 g/L (68% polymorphonuclear 
leukocytes). Two blood cultures were 
performed before antimicrobial drug 
therapy based on amoxicillin/clavu-
lanic acid and amikacin was started. 
After receiving this therapy, the pa-
tient recovered rapidly. One of the 2 
anaerobic blood cultures was positive. 
Gram-negative bacilli were isolated 
(strain 3302398). Antimicrobial sus-
ceptibility testing showed decreased 
susceptibility to vancomycin, cefo-
tetan, and penicillin G. The strain pro-
duced β-lactamase as determined by 
Ceﬁ  nase test (Becton Dickinson, Le 
Pont de Claix, France).
The second patient was a 64-year-
old man with colon cancer who was 
receiving palliative chemotherapy LETTERS
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(16th cycle, FOLFOX scheme); he was 
seen in March 2004 with a fever up to 
39°C. An adenocarcinoma of the ileum 
had been diagnosed in June 2002 in 
this patient, and an ileocecal resection 
was performed followed by adjuvant 
chemotherapy. One year later, a local 
recurrence and peritoneal carcinoma-
tosis were detected. The patient again 
underwent abdominal surgery by resec-
tion of ileo-colic anastomosis and sig-
moid and peritoneal masses; a colos-
tomy had to be created. The patient’s 
leukocyte count was 14.94 g/L (84.6% 
polymorphonuclear leukocytes), and 
his C-reactive protein level was 268 
mg/L. Before antimicrobial drug ther-
apy with amoxicilline/clavulanic acid 
and ciproﬂ   oxacin was begun, blood 
cultures were taken. One of the 2 an-
aerobic blood cultures was positive. 
Gram-negative bacilli were isolated 
(strain 4401054). Antimicrobial drug 
resistance was detected only to vanco-
mycin. After receiving this therapy, the 
patient recovered rapidly.
Biochemical characterization was 
conducted by using API 20A and rap-
id ID 32A strips (bioMérieux, Marcy 
l’Etoile, France). Results were com-
pared with those obtained for the refer-
ence strain A. ﬁ  negoldii CIP 107999T. 
Strains 3302398 and 4401054 were 
indole positive and bile resistant, and 
they had positive enzyme reactions 
for N-acetyl-β-glucosaminidase,  α-
galactosidase, and β-galactosidase, as 
described for A. ﬁ  negoldii (4). The 2 
strains produced a brown pigment af-
ter 2 weeks’ incubation on sheep blood 
agar plates (bioMérieux).
PCR ampliﬁ   cation of the 16S 
rDNA was performed with the primer 
pair fD1/rp2 (5). The generated frag-
ments were sequenced as previously 
described (6). Sequences were com-
pared with those available in GenBank 
databases by using BLAST (www.
ncbi.nlm.nih.gov/blast). They showed 
a 97% identity to the 16S rDNA of A. 
ﬁ  negoldii (accession nos. AY643083 
and AY643084).
A novel bacterium was character-
ized from appendiceal tissues samples 
from children with appendicitis and in 
2 cases of perirectal and brain abscess-
es associated with other anaerobes (1). 
With routine tests, this organism re-
sembled members of the Bacteroides 
fragilis group; however, the cellular 
fatty acid composition dominated by 
iso-C15:0 and production of brown pig-
ment on media containing hemolyzed 
blood suggested that the organism was 
most closely related to the genus Por-
phyromonas (1). However, 16S rDNA 
sequence comparison showed highest 
sequence relatedness with B. putredi-
nis, and the reclassiﬁ  cation of B. pu-
tredinis in a novel genus, Alistipes, and 
the classiﬁ  cation of the novel bacteri-
um as A. ﬁ  negoldii were proposed (4). 
A. putredinis was characterized in the 
indigenous ﬂ  ora of the human gut (7). 
The natural habitat of A. ﬁ  negoldii is 
unknown but is probably the same. B. 
fragilis is the most frequent anaerobic 
bacterium isolated from blood sam-
ples, and the principal source of the 
bacteria is the gastrointestinal tract (8). 
Predisposing factors to Bacteroides 
species bacteremia include malignant 
neoplasms, recent gastrointestinal or 
obstetric-gynecologic surgery, intesti-
nal obstruction, and use of cytotoxic 
agents or corticosteroids (8). In both 
of our patients, fever was noted and no 
other microorganisms were isolated, 
indications that the bacteria probably 
were pathogenic. 
Phenotypic identiﬁ  cation of Alis-
tipes sp. is difﬁ  cult in a routine micro-
biology laboratory. However, a mo-
lecular approach based on 16S rRNA 
gene sequence comparison is a good 
method for identifying anaerobic bac-
teria, as it has recently been reported 
for B. fragilis in anaerobic sepsis (9) 
and for B. thetaiotaomicron from a pa-
tient with a cholesteatoma and puru-
lent meningitis (10). In our 2 patients, 
we also used molecular identiﬁ  cation 
because A. ﬁ  negoldii was not includ-
ed in the API phenotypic database 
identiﬁ  cation. A. ﬁ  negoldii should be 
considered as an agent of bacteremia 
in patients with gastrointestinal patho-
logic conditions.
This work was supported by grant 
PBBSB-102600 from the Swiss National 
Science Foundation.
Figure. Phylogenetic tree inferred from comparison of the 16S rRNA gene sequences of 
genera Bacteroides, Parabacteroidetes, Prevotella, and Alistipes. Nucleotide accession 
numbers for the sequences used to construct this dendrogram are given in parentheses. 
The tree was constructed with MEGA version 2.1 (www.megasoftware.net). Distance 
matrices were determined following the assumptions described by Kimura (3) and were 
used to elaborate the dendrogram with the neighbor-joining method. Bar, 0.05-nt change 
per nucleotide position. Streptococcus pneumoniae was used as the outgroup.LETTERS
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Shiga Toxin–
producing 
Escherichia coli, 
Idaho
To the Editor: Data collected 
from expanded surveillance study 
suggest that more than half of Idaho 
Shiga toxin–producing Escherichia 
coli  (STEC) illnesses are caused by 
non-O157 serotypes. Using data from 
a regional medical center whose stool 
culture protocol included Shiga toxin 
testing, we predicted Idaho’s STEC 
incidence to be signiﬁ  cantly higher if 
non-O157 STEC E. coli were routine-
ly detected by immunoassay. Recent 
ﬁ   ndings suggest that the prediction 
was accurate in an expanded surveil-
lance area.
Several studies have shown an 
increased incidence of non-O157 
STEC infections in the United States. 
For example, a community hospital 
in Virginia detected non-O157 sero-
types in 31% of patients with STEC 
from 1995–2002 (1). A 1998 Nebraska 
study that analyzed 30,000 diarrheal 
stool samples found that non-O157 
and O157:H7 STEC were equally 
prevalent (2). Additionally, ﬁ  ndings 
from a Connecticut study of labora-
tory-conﬁ  rmed cases (3), STEC sur-
veillance results from Montana (4), 
and a recent study from Michigan 
(5) indicate that non-O157 serotypes 
comprise a substantial percentage of 
STEC cases. 
In other countries, nonculture-
based methods are routinely used for 
STEC detection (6). However, E. coli 
O157:H7 culture methods remain the 
focus in the United Kingdom, Canada, 
and the United States (6). Reliance on 
culture methods can result in mislead-
ing interpretations of STEC preva-
lence. For example, 93% of STEC 
infections in Canada are reported to 
be E. coli O157:H7, yet a Manitoba 
1992 study showed that when toxin 
assays were used, 35% of the recov-
ered STEC isolates were non-O157 
serotypes (6).
Analysis of reported non-O157 
STEC cases in Idaho showed a simi-
lar trend. From 2002–2004, 66% of 
Idaho’s non-O157 cases originated 
in Health District 7, where >70% of 
stool cultures are screened by enzyme 
immunoassay (EIA) for Shiga toxin 
(Premier EHEC, Meridian Bioscience, 
Cincinnati, OH, USA). This rate was 
disproportionately higher than that 
of the remaining 6 health districts, 
which primarily use culture methods 
to screen for E. coli O157:H7. We 
hypothesized that this disproportion 
was due to differences in stool culture 
protocol. To test this premise, we con-
ducted enhanced surveillance for 16 
months in a “low” STEC incidence 
area, Health District 5. A total of 2,065 
stools submitted for culture were 
screened for Shiga toxin by EIA. With 
this approach, reported non-O157 
STEC incidence rose from <1 case/
year/100,000 population to 11 cases/
year/100,000 population. Addition-
ally, 56% of recovered STEC isolates 
were non-O157 serotypes, mirroring 
the proportion of non-O157 detected 
in District 7. Notably, this appears to 
be the endemic rate for District 5 be-
cause no non-O157 STEC outbreaks 
or matching pulsed-ﬁ  eld gel electro-
phoresis patterns were detected dur-
ing the surveillance period. Although 
our study captured only a portion of 
stool cultures in Idaho, our ﬁ  ndings 
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